The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC


William G. Wierda, MD, PhD, discussed the emerging role of small molecule combinations and fixed-duration treatments in patients with relapsed/refractory CLL.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.